Recruiting Psoriasis Studies in Jacksonville
About Psoriasis Clinical Trials in Jacksonville
Psoriasis is a chronic autoimmune skin condition affecting over 8 million Americans, causing cells to build up rapidly on the surface and forming red, scaly patches that can be itchy and painful. Plaque psoriasis accounts for about 80-90% of cases. While current treatments include topical therapies, phototherapy, and biologics like TNF inhibitors (adalimumab, etanercept) and IL-17/IL-23 inhibitors (secukinumab, guselkumab), clinical trials are testing next-generation oral treatments, TYK2 inhibitors, and combination approaches that may offer longer remission periods with fewer side effects. Patients with moderate-to-severe psoriasis who have not responded adequately to existing therapies are often sought for clinical trial enrollment.
There are currently 1 psoriasis clinical trials recruiting participants in Jacksonville, FL. These studies are seeking a combined 150 participants. Research is being sponsored by UCB Biopharma SRL. Clinical trial participation is free and participants receive study-related medical care at no cost.
Psoriasis Clinical Trials in Jacksonville — FAQ
Are there psoriasis clinical trials in Jacksonville?
Yes, there are 1 psoriasis clinical trials currently recruiting in Jacksonville, FL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Jacksonville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Jacksonville research site will contact you about next steps.
Are clinical trials in Jacksonville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Jacksonville studies also compensate for your time and travel.
What psoriasis treatments are being tested?
The 1 active trials in Jacksonville are testing new therapies including novel drugs, biologics, and treatment approaches for psoriasis.
Data updated March 2, 2026 from ClinicalTrials.gov